Vicore Pharma Holding Ab · OMXSTO:VICO

Vicore Pharma Holding Ab — ERS Congress 2026

7 slides from Vicore Pharma Holding Ab's conference presentation, September 2026

  1. Slide 1: ASPIRE Phase 2b trial of buloxibutid in IPF: trial design and patient characteristics

    ASPIRE, a global, double-blind, randomized, placebo-controlled Phase 2b trial of buloxibutid, an angiotensin II type 2 receptor agonist, in idiopathic pulmonary fibrosis: trial design and patient characteristics T. Maher 1 , M. Wijsenbeek -Lour ens 2 , T. Kulkar ni 3 , T. Cor te 4 , F. Mar tinez 5 ,

  2. Slide 2: Buloxibutid is an Oral Small Molecule AT2R Agonist Designed to Support Tissue Repair

    Buloxibutid is an Oral Small Molecule AT2R Agonist Designed to Support Tissue Repair Through Alveolar Epithelial Type 2 cells (AEC2) Buloxibutid: Stabilization and improvement of FVC Buloxibutid is designed to target AT2R on AEC21,2 Expected effects in IPF1,2 in the open label Phase 2a AIR study 3–5

  3. Slide 3: The ASPIRE Trial in Patients with IPF was Designed to Assess Changes in FVC over 52 Weeks

    The ASPIRE Trial in Patients with IPF was Designed to Assess Changes in FVC over 52 Weeks Trial design Key inclusion and exclusion criteria Randomization 1:1:1 n=360 Primary endpoint • Age ≥ 40 years Absolute change from baseline Buloxibutid 50 mg BID (n=120) in FVC at Week 52 • Diagnosed with IPF w

  4. Slide 4: ASPIRE is a Global Trial Representing a Broad IPF Patient Population

    ASPIRE is a Global Trial Representing a Broad IPF Patient Population Characteristics, N=377* > 100 study sites across 14 countries Mean (SD) age at study entry: 71.1 (7.5) years USA & Canada, 28% Europe, 31% Mean (SD) BMI: Asia-Pacific Region, 11% 21.8% female 78.2% male 27.9 (4.8) kg/m 2 Race Black

  5. Slide 5: ASPIRE Baseline Patient Data are Reflective of a Typical Cohort of Patients with IPF

    ASPIRE Baseline Patient Data are Reflective of a Typical Cohort of Patients with IPF Time since diagnosis O2 Oxygen saturation, mean (min – max) 2.4 (1.7) years FVC, mean (SD) 96.0% (86% – 100%) 2.9 L (0.8) FVCpp, mean (SD) Previous and current IPF therapy at study entry Smoking status 81.3% (17.6)

  6. Slide 6: Conclusions

    Conclusions Buloxibutid is an angiotensin II type 2 receptor agonist designed to support tissue repair through alveolar epithelial type 2 cells ASPIRE is an ongoing randomized, placebo-controlled Phase 2b study that is designed to assess the efficacy and safety of two doses of buloxibutid over 52 we

  7. Slide 7: ERS Congress 2026, 5-9 September, Barcelona, Spain

    @ ERS CONGRESS |2026 5-9 September | Barcelona, Spain

Vicore Pharma — ERS Congress 2026 on 6ix